Document Detail

Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins.
MedLine Citation:
PMID:  1572085     Owner:  NLM     Status:  MEDLINE    
Recombinant interferon-gamma (rIFN-gamma) has been described to enhance phagocyte functions in vitro and in vivo in several patients with chronic granulomatous disease (CGD). To demonstrate the clinical usefulness of this treatment, 128 patients were treated in a randomized, double-blind multi-centre study with a placebo preparation or with rIFN-gamma. We analysed parameters of neutrophil oxidative and non-oxidative metabolism in 16 patients enrolled in this study. No enhanced superoxide-release was observed in patients treated with rIFN-gamma compared to placebo-treated patients. Phagocyte cytochrome b558 content also remained unchanged. Levels of four non-oxidative antimicrobial proteins (cathepsin G, azurocidine, p29b, lactoferrin) rose, fell, or remained unchanged, irrespective of treatment with rIFN-gamma or placebo.
T J Mühlebach; J Gabay; C F Nathan; C Erny; G Dopfer; H Schroten; V Wahn; R A Seger
Related Documents :
24618605 - A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointe...
23103315 - Abdominal auras in patients with mesial temporal sclerosis.
24948705 - Virological outcome at week 48 of three recommended first-line regimens using ultrasens...
23962145 - Baseline [(123) i]fp-cit spect (datscan) severity correlates with medication use at 3 ...
10609785 - Unexpected high incidence of severe toxicities associated with alpha interferon, low-do...
8330575 - Surgical treatment for epilepsy in cerebral tuberous sclerosis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  88     ISSN:  0009-9104     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  1992 May 
Date Detail:
Created Date:  1992-06-02     Completed Date:  1992-06-02     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  203-6     Citation Subset:  IM    
Division of Immunology-Haematology, University Children's Hospital, Zürich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Proteins / drug effects,  immunology
Cytochrome b Group / deficiency,  drug effects
Granulomatous Disease, Chronic / drug therapy*,  immunology
Immunoglobulin G / drug effects
Interferon-gamma, Recombinant / therapeutic use*
NADH, NADPH Oxidoreductases / drug effects
NADPH Oxidase
Neutrophils / drug effects
Reg. No./Substance:
0/Blood Proteins; 0/Cytochrome b Group; 0/Immunoglobulin G; 0/Interferon-gamma, Recombinant; 9064-78-2/cytochrome b558; EC 1.6.-/NADH, NADPH Oxidoreductases; EC Oxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  B cell responses to HIV and the development of human monoclonal antibodies.
Next Document:  Acute rejection in heart transplant patients is associated with the presence of committed donor-spec...